What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?

Abstract

Coronavirus disease 2019 is a respiratory infection caused by severe acute respiratory syndrome coronavirus2. Coronavirus disease 2019 leads to the rapid activation of innate immune cells, particularly in patients withsevere disease. Psoriatic arthritis is a heterogeneous chronic inflammatory disease characterized by the association of psoriasis and arthritis. Similar to those with other viruses, patients with psoriatic arthritis are ata significant risk of infection with severe acute respiratory syndrome coronavirus 2. Patients with psoriaticarthritis are immunosuppressed owing to immune dysregulation during the active disease period or owing toimmunosuppressive drugs administered during remission, and they are prone to infections. The severe acuterespiratory syndrome coronavirus 2 is a threat to millions of people globally owing to the decline in immunityand because a significant number of people develop severe illness. In the period of coronavirus disease 2019pandemic, we briefly present recommendations for the treatment of psoriatic arthritis. In this review, webriefly address the management options and treatment recommendations for patients with psoriatic arthritisduring and after the coronavirus disease 2019 pandemic in light of recent scientific publications.